CEO Address to Shareholders
Released
Released
Announcement PDF
CEO REMARKS 2026 AGM
ASX Release
12 November 2026
ASX:TTX
Tetratherix Limited 2026 Anchored by Science
In accordance with Listing Rule 3.13.3, please see the remarks to be presented at the Tetratherix
Limited (ASX:TTX) (Tetratherix) 2026 AGM by Will Knox our CEO.
A year ago we listed on the ASX with a clear thesis and FY26 was the year we put it to work.
The thesis was simple, and to some it sounded unconventional. One chemistry, invented and made
in Sydney, programmed into many products and carried into the world by the strongest partner in
each field. Fifteen years of work went into that chemistry and FY26 has laid the foundation for that
thesis to propel us into the future of healthcare upon our Tetramatrix innovation - the building
blocks for medicine.
We completed our first full FDA submissions in our bone regeneration franchise. Behind them sit
twenty-seven technical reports, the complete ISO 10993 safety package and two FDA
performance studies. In our precision medicine program, the FDA has also now assigned the
Tetramatrix polymer its own federal identifier as a approved excipient as we begin to change the
way drugs and biologics are delivered in metabolic health & consumer medicine. The progress we
have made in bringing an entirely new chemical entity to the world's most rigorous regulator speaks
to the work that has been done behind the scenes, over many years with world leading researchers
- the significance of which can not be overstated.
In FY26 We became a revenue-generating company. Our precision medicine program has
launched with sophisticated partnerships building commercial and technical infrastructure. We
signed an exclusive global supply agreement with Henry Schein, one of the largest medical and
dental companies in the world. We licensed our ophthalmic technology to BioOptix, which has
partnered with Alcon - the leading player in the ophthalmic space globally, with whom our
Optimatrix program is being executed.
Our clinical evidence compounded. Tutelix completed its first-in-human pilot study with no
product-related adverse events and proven efficacy aligned with our design & development
objectives, and holds ethics approval for its pivotal trial that is getting underway in 2026.
TetraDerm completed its full enrolment and has moved into the largest wounds in surgery with
blinded results coming in 2027 in line with the opening of our strategic partnership window. More
than 75 patients have now been treated with Tetramatrix, a 58 per cent increase on the year
before. And five years of quiet work in nasal drug delivery became a new franchise, Precision
Medicine, with STEPP at its centre.
All of this has been done on budget and slightly ahead of time for many programs which speaks to
our execution-focused culture at TTX. We closed the year with $34.4 million in cash, having
secured more than $20 million beyond our prospectus assumptions.
The economics of this company are the part of our story I believe compounds our differentiation
and are deliberately designed to scale. Our six first-generation products come from three polymer
configurations that share around 95 per cent of their chemistry. Our partners carry regulation,
reimbursement and distribution in their own markets. As they sequentially launch over the coming
years, each new partner adds revenue onto the same core chemistry, the same safety data and
the same production line. We built Tetratherix to be capital-light by design. Over the coming years,
as licence income is joined by product supply, that design will show up in our numbers.
FY27 is the year our science turns into revenue, and the platform reaches several inflection points
at once.
Tetratherix Limited 2026 Anchored by Science
InvestorHub
The Tetratherix InvestorHub platform provides existing and prospective shareholders with
real‑time access to ASX announcements, reports and presentations. You can visit the Tetratherix
Investor Hub at:
Authorised for release by the CEO.
For further information contact:
Jacob Pfeffer
General Counsel | Chief of Staff | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com
The first is commercialisation. We are rapidly working toward FDA clearance for our bone
regeneration products, followed by a disciplined US seeding program across dental as well as
orthopaedics and our first regenerative product sales. STEPP is well placed for its commercial
polymer supply as the precision medicine franchise builds.
The second is platform growth. Tutelix will enrol its first pivotal trial patients. Optimatrix rapidly
moves toward the clinic. In orthopaedics, TegenEOS extends into platelet-rich plasma delivery,
where our recent preclinical tendon results point to simpler, earlier treatment in ambulatory
settings, which has guided our orthopaedic partnership due diligence program in FY26.
Following, the third is new partners. We are selecting a long-term strategic partner for TegenEOS,
and conversations across the rest of the platform deepened through the year, specifically in
precision medicine and tissue healing as TetraDerm proved itself as a healing innovation. We
choose partners for a fifteen-to-twenty-year horizon, and we will announce them when the work is
complete, aligned with our long term, compounding strategy.
The fourth is the transition to commercial supply and revenue itself. Our advanced manufacturing campus in
Alexandria brings headquarters and production under one roof and lifts our capacity tenfold. With MDSAP
certification now officially installed into the system, it opens the United States, Australia and other major
markets together as we grow the supply capabilities for our partners.
Every result I have described belongs to our people. A team of less than 30 people took a research
house and evolved it into a manufacturing-led commercial company inside a single year. The same
scientists who defined our design & development systems now run qualified production lines, sit
across the table from regulators and hold global partners to the standard our science demands. To
every member of the Tetratherix team: you are remarkable, and I am immensely proud to work
beside you.
The market rewards conviction when evidence stands behind it. We intend to keep supplying both.
To our shareholders - thank you. Thank you for your support, aligned vision on what medicine
should look like and your belief in us. Our mission is to treat ten million patients by 2035 and each of
them will receive care that is faster, gentler and safer because you backed this company early.
That is what your capital is building.
< ENDS >
ASX Release
ASX:TTX
Share your feedback
Discover